You seem to be using an older version of Internet Explorer. This site requires Internet Explorer 8 or higher. Update your browser here today to fully enjoy all the marvels of this site.
Please donate at http://www.ourccia.org.au/hunter and help raise $200,000 so that scientists at CCIA can continue creating better and more personalised treatments for children with cancer.
At the conclusion of the clinical trial Study 8, survival rates for children with high-risk acute lymphoblastic leukaemia whose Minimal Residual Disease (MRD) tests at diagnosis predicted a high risk of relapse have gone from just below 40 per cent to at an incredible 70 per cent.
Study 9 will continue on this path to improving outcomes, whilst reducing the intensity of treatment given to children identified as having a lower risk of relapse - but we can't do it without you.